rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-325-330rsp-3581Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL OBSERVATIONБеременность и ее исход при антифосфолипидном синдроме после острого нарушения мозгового кровообращения (клиническое наблюдение)Pregnancy and its outcome in antiphospholipid syndrome after acute cerebral circulatory failure (clinical case study)https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

Решетняк Татьяна Магомедалиевна

115522, Москва, Каширское шоссе, 34а

 

Tatiana M. Reshetnyak

115522, Moscow, Kashirskoye Highway, 34A

 

t_reshetnyak@yahoo.comhttps://orcid.org/0000-0001-5217-4932ЧельдиеваФ. А.CheldievaF. A.

115522, Москва, Каширское шоссе, 34а

Fariza A. Cheldieva

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-6018-3895КошелеваН. М.KoshelevaN. M.

115522, Москва, Каширское шоссе, 34а

Nadezhda M. Kosheleva

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0003-1318-1894ШумиловаА. А.ShumilovaA. A.

115522, Москва, Каширское шоссе, 34а

Anastasiia A. Shumilova

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-4503-7750БланкЛ. М.BlankL. M.

115522, Москва, Каширское шоссе, 34а

Leonid M. Blank

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0001-5781-2964СередавкинаН. В.SeredavkinaN. V.

115522, Москва, Каширское шоссе, 34а

Nataliya V. Seredavkina

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202427062024623325330Copyright © Решетняк Т.М., Чельдиева Ф.А., Кошелева Н.М., Шумилова А.А., Бланк Л.М., Середавкина Н.В., 20242024Решетняк Т.М., Чельдиева Ф.А., Кошелева Н.М., Шумилова А.А., Бланк Л.М., Середавкина Н.В.Reshetnyak T.M., Cheldieva F.A., Kosheleva N.M., Shumilova A.A., Blank L.M., Seredavkina N.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3581

Акушерская патология (потери беременности на разных сроках гестации, преждевременные роды морфологически нормального плода из-за пре-/эклампсии или плацентарной недостаточности) наряду с тромботическими осложнениями является основным клиническим проявлением антифосфолипидного синдрома (АФС). Большинство исследований беременности при АФС сосредоточены на женщинах с рецидивирующими потерями плода; данные об исходах беременности у пациенток с другими клиническими фенотипами АФС, например с тромботическим АФС, ограничены. Представляем клиническое наблюдение больной достоверным тромботическим АФС (с рецидивирующими ишемическими нарушениями мозгового кровообращения) и высокопозитивными уровнями антифосфролипидных антител с благоприятным исходом беременности. 

Obstetric pathology (pregnancy loss at different gestational ages; premature delivery of morphologically normal foetus due to pre-/eclampsia or placental insufficiency), along with thrombotic complications are the main clinical manifestations of antiphospholipid syndrome (APS). Among arterial thromboses in APS, cerebral vascular thromboses in the form of strokes or transient ischaemic attacks. Patients with APS have a well known increased risk of thrombosis associated with pregnancy or conditions accompanied by hyperestrogenemia. More than half of thrombotic complications in women with APS occur during gestation or hyperestrogenemia. Most studies of pregnancy in APS have focused on women with recurrent fetal loss, and data on pregnancy outcomes in patients with other clinical phenotypes of APS, such as thrombotic APS, are limited. We present a case report of a patient with reliable thrombotic APS (with recurrent ischaemic cerebral circulatory disorders) and highly positive levels of antiphosphrolipid antibodies with a favourable pregnancy outcome.

антифосфолипидный синдромантифосфолипидные антителанарушение мозгового кровообращениябеременностьantiphospholipid syndromeantiphospholipid antibodiescerebrovascular accidentpregnancyСтатья подготовлена в рамках темы ФГБНУ НИИР им. В.А. Насоновой FURS-2022-003 (№ 122040400024-7)ReferencesMiyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xMiyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.xPetri M. Antiphospholipid syndrome. Transl Res. 2020;225:70-81. doi: 10.1016/j.trsl.2020.04.006Petri M. Antiphospholipid syndrome. Transl Res. 2020;225:70-81. doi: 10.1016/j.trsl.2020.04.006Suzumori N, Sugiura-Ogasawara M. Genetic factors as a cause of miscarriage. Curr Med Chem. 2010;17(29):3431-3437. doi: 10.2174/092986710793176302Suzumori N, Sugiura-Ogasawara M. Genetic factors as a cause of miscarriage. Curr Med Chem. 2010;17(29):3431-3437. doi: 10.2174/092986710793176302Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod. 1999;14(11):2868-2671. doi: 10.1093/humrep/14.11.2868Brigham SA, Conlon C, Farquharson RG. A longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage. Hum Reprod. 1999;14(11):2868-2671. doi: 10.1093/humrep/14.11.2868Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al.; Lancet Ending Preventable Stillbirths Series study group; Lancet Stillbirth Epidemiology investigator group. Stillbirths: Rates, risk factors, and acceleration towards 2030. Lancet. 2016;387(10018):587-603. doi: 10.1016/S0140-6736(15)00837-5Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al.; Lancet Ending Preventable Stillbirths Series study group; Lancet Stillbirth Epidemiology investigator group. Stillbirths: Rates, risk factors, and acceleration towards 2030. Lancet. 2016;387(10018):587-603. doi: 10.1016/S0140-6736(15)00837-5Liu L, Sun D. Pregnancy outcomes in patients with primary antiphospholipid syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(20):e15733. doi: 10.1097/MD.0000000000015733Liu L, Sun D. Pregnancy outcomes in patients with primary antiphospholipid syndrome: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(20):e15733. doi: 10.1097/MD.0000000000015733Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, et al.; EUROAPS Study Group. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases. Autoimmun Rev. 2019;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006Maynard S, Guerrier G, Duffy M. Pregnancy in women with systemic lupus and lupus nephritis. Adv Chronic Kidney Dis. 2019;26(5):330-337. doi: 10.1053/j.ackd.2019.08.013Maynard S, Guerrier G, Duffy M. Pregnancy in women with systemic lupus and lupus nephritis. Adv Chronic Kidney Dis. 2019;26(5):330-337. doi: 10.1053/j.ackd.2019.08.013Решетняк ТМ, Кошелева НМ, Насонов ЕЛ. Системная красная волчанка и беременность: до, во время гестации и после родов. Научно-практическая ревматология. 2023;61(3):292- 297 doi: 10.47360/1995-4484-2023-292-297Reshetnyak TM, Kosheleva NM, Nasonov EL. Systemic lupus erythematosus and pregnancy: Before gestation, during and after childbirth. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(3):292-297 (In Russ.). doi: 10.47360/1995-4484-2023-292-297Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027. doi: 10.1002/art.10187Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al.; Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027. doi: 10.1002/art.10187Fischer-Betz R, Specker C, Brinks R, Schneider M. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: An observational study. Lupus. 2012;21(11):1183-1189. doi: 10.1177/0961203312451335Fischer-Betz R, Specker C, Brinks R, Schneider M. Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: An observational study. Lupus. 2012;21(11):1183-1189. doi: 10.1177/0961203312451335Levine SR, Brey RL, Joseph CL, Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke. 1992;23(Suppl 2):I29-I32.Levine SR, Brey RL, Joseph CL, Havstad S. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. The Antiphospholipid Antibodies in Stroke Study Group. Stroke. 1992;23(Suppl 2):I29-I32.Lockshin MD, Qamar T, Levy RA, Druzin ML. Pregnancy in systemic lupus erythematosus. Clin Exp Rheumatol. 1989;7(Suppl 3):S195-S197.Lockshin MD, Qamar T, Levy RA, Druzin ML. Pregnancy in systemic lupus erythematosus. Clin Exp Rheumatol. 1989;7(Suppl 3):S195-S197.Branch DW, Khamashta MA. Antiphospholipid syndrome: Obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003;101(6):1333-1344. doi: 10.1016/s0029-7844(03)00363-6Branch DW, Khamashta MA. Antiphospholipid syndrome: Obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003;101(6):1333-1344. doi: 10.1016/s0029-7844(03)00363-6Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131-136.Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131-136.Ghembaza A, Saadoun D. Management of antiphospholipid syndrome. Biomedicines. 2020;8(11):508. doi: 10.3390/biomedicines8110508Ghembaza A, Saadoun D. Management of antiphospholipid syndrome. Biomedicines. 2020;8(11):508. doi: 10.3390/biomedicines8110508Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on Hep-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev. 2012;11(9):642-645. doi: 10.1016/j.autrev.2011.11.005Mahler M, Hanly JG, Fritzler MJ. Importance of the dense fine speckled pattern on Hep-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev. 2012;11(9):642-645. doi: 10.1016/j.autrev.2011.11.005Решетняк ТМ, Шумилова АА, Кошелева НМ. Клиническое значение антинуклеарных антител. Лечебное дело. 2021;4:96- 103. doi: 10.24412/2071-5315-2021-12398Reshetnyak TM, Shumilova AA, Kosheleva NM. Clinical value of antinuclear antibodies. Lechebnoe delo. 2021;4:96-103 (In Russ.). doi: 10.24412/2071-5315-2021-12398

The authors declare that there are no conflicts of interest present.